natgillin/translations-raw huggingface dataset:
Nivolumab monotherapy should be withheld for Grade 3 diarrhoea or colitis, and corticosteroids initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
U slučaju proljeva ili kolitisa 3. stupnja, potrebno je odgoditi primjenu nivolumaba u monoterapiji i uvesti liječenje kortikosteroidima u dozi od 1 do 2 mg/kg/dan ekvivalenata metilprednizolona.
Nivolumab must be permanently discontinued for any severe immune related adverse reaction that recurs and for any life threatening immune related adverse reaction.
Liječenje nivolumabom mora se trajno prekinuti u slučaju bilo koje teške imunološki uzrokovane nuspojave koja se ponovi kao i u slučaju po život opasne imunološki uzrokovane nuspojave.
Nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-related adverse reaction.
Liječenje nivolumabom ili nivolumabom u kombinaciji s ipilimumabom mora se trajno prekinuti u slučaju bilo koje teške imunološki uzrokovane nuspojave koja se ponovi kao i u slučaju po život opasne imunološki uzrokovane nuspojave.
Nivolumab+ipilimumab vs ipilimumab (primary analysis) - HR (99.5% CI): 0.42 (0.32, 0.56); p-value: <0.0001
Nivolumab + ipilimumab naspram ipilimumaba (primarna analiza) – HR (99,5% CI): 0,42 (0,32; 0,56); p-vrijednost: < 0,0001
Nizatidine Ranitidine
Nizatidin Ranitidin
NL - 1077 ZX Amsterdam, The Netherlands
NL - 1077 ZX Amsterdam, Nizozemska
NL-1316 BN Almere The Netherlands‌
NL-1316 BN Almere Nizozemska
NL-1327 AH Almere Tel: +31 36 5241600
NL-1327 AH Almere Tel: + 31 36 5241600
NL-1327 AH Almere Tel: +31 36 5241600 info.sandoz-nl@sandoz.com
NL-1327 AH Almere Tel: + 31 36 5241600
NL-1411 DD Naarden The Netherlands
NL-1411 DD Naarden Nizozemska
NL-1411DD Naarden The Netherlands
NL-1411DD Naarden Nizozemska
NL-2031 Haarlem The Netherlands
NL-2031 Haarlem Nizozemska
NL-2132 JH Hoofddorp The Netherlands
2132 JH Hoofddorp Nizozemska
NL-2333 CN Leiden Netherlands
NL-2333 CN Leiden Nizozemska
NL-2333 CR Leiden The Netherlands
NL-2333 CR Leiden Nizozemska
NL-3503RN Utrecht Nederland
NL-3503RN Utrecht, The Netherlands
NL-3771 ND-Barneveld Tel: 31 (0) 342 427 100
NL-3771 ND-Barneveld Tel: 31 (0) 342 427 127
NL-3771 ND-Barneveld Tel: 31 (0) 342 427 100
Tel: + 45 7552 1244
NL-5612 AZ, Eindhoven The Netherlands
NL-5612 AZ, Eindhoven Nizozemska
NMBA and dose to be administered
Neuromuskularni blokator i doza koju treba primijeniti
NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.
NMDA-receptorima, doprinosi izraženosti simptoma i progresiji bolesti kod neurodegenerativne demencije.
NMS (Neuroleptic Malignant Syndrome):
NMS (neuroleptički maligni sindrom):
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.
NMS je potencijalno smrtonosni skup simptoma povezan s antipsihoticima.
NMS is a potentially fatal symptom complex associated with antipsychotic medicinal products.
NMS je potencijalno smrtonosni zbir simptoma povezan s antipsihotičkim lijekovima.
NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
NMS je potencijalno po život opasno stanje povezano s primjenom antipsihotika.
NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g. agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase.
Za NMS, uključujući rabdomiolizu i hipertermiju, karakteristični su motorički simptomi (rigidnost, mioklonus, tremor), promjene mentalnog stanja (npr. agitiranost, konfuzija, koma), hipertermija, autonomna disfunkcija (tahikardija, varijabilni krvni tlak) i povišena kreatin fosfokinaza u serumu.
NN:>
2019.
NNRTI + PI
NNRTI + IP
NNRTI-based
utemeljena na NNRTI
NNRTIs
NNRTI-i
NNRTIs other than rilpivirine (efavirenz, etravirine, and nevirapine) are contraindicated (see section 4.3).
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI), osim rilpivirina, (efavirenz, etravirin i nevirapin) su kontraindicirani (vidjeti dio 4.3)
NNRTIs/Efavirenz
didanozin/tenofovirdizoproksil fumarat
NNRTIs/Efavirenz
simeprevira.
NNRTIs: careful monitoring for any occurrence of drug toxicity and/or lack of anti-viral efficacy, and dose adjustment if required.
NNRTI-ovi: paţljivo praćenje radi mogućeg razvoja toksičnosti lijeka i/ili izostanka antivirusne djelotvornosti te po potrebi prilagoĎavanje doze.
No
Da Ne
No (for any parameter listed above)
Ne (za bilo koji od navedenih parametara)
No (for any parameter listed above)
Ne (za neki od navedenih parametara)
No 1359 0.71 [0.58;0.86] 0.41
Ne 1359 0,71 [0,58;0,86] 0,41
No 1412 0.79 [0.66;0.95] 0.59
Ne 1412 0,79 [0,66;0,95] 0,59
No 1853 0.77 [0.65;0.92] 0.85
Ne 1853 0,77 [0,65;0,92] 0,85
No 3146 0.77 [0.68;0.87] 0.71
Ne 3146 0,77 [0,68;0,87] 0,71
No 3473 0.76 [0.68;0.85] 0.85
Ne 3473 0,76 [0,68;0,85] 0,85
No 3990 0.78 [0.70;0.87] 0.15
Ne 3990 0,78 [0,70;0,87] 0,15
No 3999 0.76 [0.68;0.84] 0.96
Ne 3999 0,76 [0,68;0,84] 0,96
No a-priori dose adjustment is required on the basis of a patient’s age.
Nije potrebna a- priori prilagodba doze na temelju dobi bolesnika.
No accumulation for Cmax was observed.
Nije primijećena akumulacija za Cmax.
No accumulation of dalbavancin was observed following multiple intravenous infusions administered once-weekly for up to 8 weeks (1000 mg on Day 1, followed by up to 7 weekly 500 mg doses) in healthy adults.
Nije primijećena akumulacija dalbavancina nakon višestrukih intravenskih infuzija primijenjenih jednom tjedno u trajanju do 8 tjedana (1000 mg prvi dan, nakon čega je slijedilo do 7 tjednih doza od 500 mg) kod zdravih odraslih osoba.
No accumulation of elosulfase alfa in plasma was evident following weekly dosing.
Nije primijećena akumulacija elosulfaze alfa u plazmi nakon tjednog doziranja.
No accumulation of teduglutide was observed following repeated subcutaneous administrations.
Nakon višestruke supkutane primjene nije zabilježena akumulacija teduglutida.
No accumulation was observed in the blood of dogs treated for 6 months with oclacitinib.
Nije uočeno nakupljanje u krvi pasa nakon šestomjesečnog davanja oclacitiniba.
No additional contraceptive use is required.
Dodatna kontracepcija nije potrebna.
No additional dose adjustments are recommended for older people.
Ne preporučuju se dodatna prilagođavanja doze za starije osobe.
No additional food should be consumed for up to 2 hours after administration of efavirenz..
Nikakva dodatna hrana ne smije se uzimati u razdoblju do 2 sata nakon uzimanja efavirenza.
No additional studies were needed as Bortezomib Accord is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.
Nisu bila potrebna dodatna ispitivanja jer je Bortezomib Accord generički lijek koji se daje infuzijom i sadrži istu djelatnu tvar kao i referentni lijek, Velcade.
No additional studies were needed as Nordimet is a hybrid medicine that is given by injection and contains the same active substance as the reference medicine, Lantarel FS.
Nisu bila potrebna dodatna ispitivanja jer je lijek Nordimet hibridni lijek koji se daje injekcijom i koji sadrži istu djelatnu tvar kao i referentni lijek, Lantarel FS.
No additional studies were needed as Sevohale is a generic medicine that is given by inhalation and contains the same active substance as the reference medicine, SevoFlo.
Nisu bila potrebna dodatna ispitivanja jer je Sevohale generički VMP koji se daje udisanjem i sadrži istu djelatnu tvar kao i referentni VMP SevoFlo.
No additional studies were needed as Voriconazole Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine Vfend.
Nisu bila potrebna dodatna ispitivanja jer je Voriconazole Hospira generički lijek koji se daje infuzijom i sadrži istu djelatnu tvar kao i referentni lijek Vfend.
No additional studies were needed as Zoledronic Acid Accord is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
Nisu bila potrebna dodatna ispitivanja jer je Zoledronatna kiselina Accord generički lijek koji se daje infuzijom ili intravenoznom injekcijom i sadrži istu djelatnu tvar kao i referentni lijek, Zometa.
No adequate and well-controlled studies of Kalydeco in pregnant women have been conducted.
Nisu provedena odgovarajuća i dobro kontrolirana ispitivanja primjene lijeka Kalydeco u trudnica.
No adequate clinical data in exposed pregnancies are available.
Ne postoje adekvatni klinički podaci u izloženim trudnoćama.
No ADHD
Bez ADHD-a
No adjustment in starting dose is required for elderly patients.
Nije potrebno prilagođavati početnu dozu kod starijih bolesnica.
No adjustment of digoxin dose is required based on these results.
Na osnovi ovih rezultata, nije potrebno prilagođavanje doze digoksina.
No adjustment of methadone dosage is required when initiating co-administration with PREZISTA/ritonavir.
primjena s lijekom PREZISTA/ritonavir.
No adjustment of methadone dose is required
Nije potrebna prilagodba doze metadona kad
No adjustment of starting dose is required on the basis of hepatic function in patients with mild (Child- Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Nije potrebna prilagodba početne doze na temelju funkcije jetre u bolesnika s blagim (Child-Pugh A) ili umjerenim (Child-Pugh B) oštećenjem funkcije jetre.
No adjustment of starting dose of the combination is required on the basis of hepatic function in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Nije potrebna prilagodba početne doze kombinacije lijekova na temelju funkcije jetre u bolesnika s blagim (Child- Pugh A) ili umjerenim (Child-Pugh B) oštećenjem funkcije jetre.
No adjustment of the initial dosage of Rasilez is required in patients with mild to moderate renal impairment (see sections 4.2 and 4.4).
U bolesnika s blagim do teškim oštećenjem bubrežne funkcije nije potrebna prilagodba početne doze Rasileza (vidjeti dijelove 4.2 i 4.4).
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (GFR 89-60 ml/min/1.73 m2 and 59-30 ml/min/1.73 m2, respectively, see sections 4.4 and 5.2).
U bolesnika s blagim do teškim oštećenjem bubrežne funkcije nije potrebna prilagodba početne doze (GFR 89-60 ml/min/1,73 m2 i 59-30 ml/min/1,73 m2, vidjeti dijelove 4.4 i 5.2).
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2).
U bolesnika s blagim do teškim oštećenjem bubrežne funkcije nije potrebna prilagodba početne doze (vidjeti dijelove 4.4 i 5.2).
No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see section 5.2).
U bolesnika s blagim do teškim oštećenjem jetrene funkcije nije potrebna prilagodba početne doze (vidjeti dio 5.2).
No adjustment of the initial dose is required in patients >65 years of age.
U bolesnika starijih od 65 godina nije potrebna prilagodba početne doze.
No adjustment of the initial dosing is required on the basis of a patient’s age (see section 5.2).
Nije potrebno prilagoditi početnu dozu na temelju dobi bolesnika (vidjeti dio 5.2).
No adjustment of the standard dose is recommended in patients with mild renal impairment (see section 5.2).
Ne preporučuje se prilagodba standardne doze u bolesnika s blagim oštećenjem bubrega (vidjeti dio 5.2).
No adjustment of the starting dose is recommended in patients with mild hepatic impairment.
Nije potrebno prilagoditi početnu dozu u bolesnika s blagim oštećenjem jetre.
No adjustment of the starting dose is required on the basis of patient’s race (see sections 5.1 and 5.2).
Nije potrebno prilagoditi početnu dozu s obzirom na rasu bolesnika (vidjeti dijelove 5.1 i 5.2).
No adjustment to the starting dose is needed in patients with mild or moderate renal impairment (see section 5.2).
U bolesnika s blagim ili umjerenim oštećenjem bubrega nije potrebna prilagodba početne doze (vidjeti dio 5.2).
No adjustment was made for multiple testing.
Nije napravljena prilagodba za višekratna ispitivanja.
No adverse effects of memantine were noted on fertility in rats and rabbits (see section 5.3).
Nisu zabilježeni štetni učinci memantina na plodnost u štakora i kunića (vidjeti dio 5.3).
No adverse effects of memantine were noted on fertility in rats and rabbits (see section 5.3).
Nisu zabilježeni štetni učinci na plodnost u štakora i kunića (vidjeti dio 5.3).
No adverse effects on male or female mouse reproductive organs in 13 week toxicity studies with the murine surrogate molecule (see section 5.3).
U ispitivanjima toksičnosti sa mišjim surogatom u trajanju od 13 tjedana nije bilo nuspojava na reproduktivne organe mužjaka ili ženki miševa (vidjeti dio 5.3).
No adverse effects were observed after a 10-fold overdose.
Nisu uočeni štetni učinci nakon primjene 10-struke doze.
No adverse effects were observed in a fertility study in female rats at doses up to 22 times the maximum recommended human dose on a mg/m2 basis.
Nisu bili opaženi štetni učinci na ženke štakora u ispitivanju plodnosti pri dozama do 22 puta većima od maksimalne preporučene doze u ljudi primijenjene na temelju mg/m2.
No adverse effects were observed in animal studies at exposures up to 300-fold higher than those in patients treated with Repatha at 420 mg once monthly.
Nisu zamijećene nikakve nuspojave u ispitivanjima na životinjama pri izloženosti do 300 puta većoj od one u bolesnika liječenih s lijekom Repatha u dozi od 420 mg jedanput mjesečno.
No adverse effects were observed in dogs and cats aged 8 weeks or older when administered 5 times the recommended dose on 8 occasions at 4 weeks intervals or administered 5 times the recommended dose on 6 occasions at 2 weeks intervals.
Nisu zabilježene nuspojave kod pasa i mačaka u dobi od 8 tjedana ili starijih, kod primjene preporučene doze, 5 puta u 8 navrata, u intervalima od 4 tjedna ili kod primjene preporučene doze, 5 puta u 6 navrata, u intervalima od dva tjedna.
No adverse effects were observed in sexually mature female cynomolgus monkeys exposed to pertuzumab.
U spolno zrelih ženki makaki majmuna izloženih pertuzumabu nisu primijećeni štetni učinci.
No adverse effects were seen in rats given a single dose of 1000 μg/kg or in monkeys after repeated administration of romiplostim at 500 µg/kg (100 or 50 times the maximum clinical dose of 10 µg/kg, respectively).
Nisu primijećeni nikakvi štetni učinci na štakore kojima je dana jedna doza od 1000 µg/kg ili na majmune nakon opetovane primjene romiplostima u dozi 500 µg/kg (što je 100 ili 50 puta veća doza od maksimalne kliničke doze od 10 µg/kg).
No adverse effects were seen in rats given a single dose of 1000 μg/kg or in monkeys after repeated administration of romiplostim at 500 µg/kg (100 or 50 times the maximum clinical dose of 10 µg/kg, respectively).
Nisu primijećeni nikakvi štetni učinci na štakore kojima je dana jedna doza od 1000 µg/kg, ili na majmune nakon opetovane primjene romiplostima u dozi 500 µg/kg (što je 100 ili 50 puta veća doza od maksimalne kliničke doze od 10 µg/kg).
No adverse effects were seen on maternal well-being or female fertility, embryo-foetal and peri- and post-natal reproductive indices in rats using a rodent anti-rat TNFα PEGylated Fab' (cTN3 PF) following sustained TNFα suppression.
Primjenom glodavcima prilagođenog pegiliranog Fab- a na TNFα štakora (cTN3 PF) nisu zabilježene nuspojave na zdravstveno stanje majke ili plodnost ženke, embrio-fetalne te perinatalne i postnatalne reproduktivne indekse u štakora nakon produžene TNFα supresije.
No adverse events previously unreported in shorter duration and/or previous studies were observed in this long-term study.
U ovom dugotrajnom ispitivanju nisu bile opažene nuspojave prethodno nezabilježene kod kraće primjene i/ili u prethodnim ispitivanjima.
No adverse reaction was identified related to these LDL-C values.
Nisu utvrđene nuspojave povezane s tim vrijednostima LDL-C.
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a 10-fold vaccine dose.
Nakon primjene 10-terostruke doze cjepiva nisu zapažene nuspojave osim onih navedenih u dijelu 4.6.
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Nakon primjene dvostruke doze cjepiva nisu primijećene nikakve nuspojave osim onih već spomenutih u odjeljku 4.6.
No adverse reactions except those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Nikakve nuspojave osim onih opisanih u dijelu 4.6 nisu opažene nakon aplikacije dvostruke doze.
No adverse reactions except those mentioned in section ‘Adverse Reactions’ were observed after the administration of a double-dose of vaccine.
Nakon primjene dvostruke doze cjepiva nisu primijećene nuspojave osim onih već spomenutih u odjeljku “Nuspojave”.
No adverse reactions have been identified.
Nuspojave nisu utvrđene.
No adverse reactions have been noted following an 8-fold overdose.
Nisu zabilježene nuspojave nakon primjene 8-strukog predoziranja.
No adverse reactions have been observed after the administration of a 10 fold overdose of the vaccine.
Nikakve nuspojave nisu primijećene nakon primjene deseterostruke preporučene doze vakcine.
No adverse reactions have been observed after the administration of a 10 fold overdose of the vaccine.
Nisu uočene nuspojave nakon primjene 10 puta veće doze cjepiva.
No adverse reactions have been observed at up to 3-fold overdose in breeders.
Nisu uočene nuspojave kod primjene do tri puta veće doze kod rasplodnih nesilica.
No adverse reactions have been observed at up to 5-fold overdose in layers and broilers (aged 21 days).
Nisu uočene nuspojave kod primjene do 5 puta veće doze kod nesilica i brojlera (starosti 21 dan).
No adverse reactions have been observed at up to ten-fold overdose in pigs.
Nisu uočene nuspojave kod primjene do deset puta veće doze kod svinja.
No adverse reactions of memantine were noted on male and female fertility.
Nisu utvrđene nuspojave memantina na mušku i žensku plodnost.
No adverse reactions of memantine were noted on male and female fertility.
Nisu zabilježeni štetni učinci memantina na plodnost u mužjaka i ženki.
No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).
U ženki i mužjaka štakora nisu primijećene nuspojave povezane s plodnošću ili reprodukcijuom pri dozama koje uzrokuju plazmatsku izloženost (AUC) do približno 2 puta veće od plazmatske AUC pri najvišoj preporučenoj dozi u ljudi.
No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2 times the plasma AUC in humans at the maximum recommended human dose (MRHD).
U ženki i mužjaka štakora nisu primijećene nuspojavepovezane s plodnošću ili reprodukcijom pri dozama koje uzrokuju plazmatsku izloženost (AUC) do približno 2 puta veće od plazmatske AUC pri najvišoj preporučenoj dozi u ljudi.
No adverse reactions other than already mentioned under point “Adverse reactions” can be expected, except for an increase of rectal temperature up to 2ºC. This rectal temperature increase is spontaneously resolved within 24 hours without treatment.
Ne očekuju se druge nuspojave pored onih navedenih u točki “ Nuspojave“, osim porasta rektalne temperature do 2ºC. Porast rektalne temperature spontano prolazi unutar 24 sata bez liječenja.
No adverse reactions other than already mentioned under section “Adverse reactions” can be expected after the administration of a 2-fold vaccine dose.
Nakon primjene 2-struke doze cjepiva nisu zapažene nikakve druge nuspojave osim onih ranije navedenih u odlomku ,,Nuspojave".
No adverse reactions other than those described in section 4.6 have been observed following simultaneous subcutaneous administration of up to 10 times the recommended dose.
Nuspojave drugačije od onih opisanih u dijelu 4.6 nisu bile primijećene ni poslije istovremenog apliciranja 10 puta veće doze.
No adverse reactions other than those described in the section “Adverse reactions” have been observed following subcutaneous administration of up to 10 times the recommended dose.
Nuspojave drugačije od onih opisanih u djelu „Nuspojave“ nisu primijećene niti nakon istovremenog apliciranja 10 puta veće doze.
No adverse reactions other than those mentioned in section 4.6 have been observed.
Nema drugih nuspojava, osim onih navedenih u 4.6 poglavlju.
No adverse reactions other than those mentioned in section 4.6 were observed after the administration of a double dose of vaccine.
Nakon primjene dvostruke doze cjepiva nisu zapažene nuspojave osim onih navedenih u dijelu 4.6.
No adverse reactions other than those mentioned in section 4.6 were observed after the administration of an overdose of the vaccine.
Ne pojavljuju se druge nuspojave osim onih navedenih u odjeljku 4.6. gdje se spominje prekomjerno doziranje cjepiva.
No adverse reactions other than those mentioned in section 6 have been observed.
Nema drugih nuspojava, osim onih navedenih u 4.6 poglavlju.
No adverse reactions other than those mentioned in section 6 were observed after the administration of a double dose of vaccine.
Nakon primjene dvostruke doze nisu uočene neželjene pojave osim onih navedenih u odjeljku 6.
No adverse reactions other than those mentioned in section 6 were observed after the administration of a double-dose of the vaccine.
Dodatnih nuspojava u odnosu na one spomenute u odjeljku 4.6 nije bilo nakon aplikacije dvostruke doze cjepiva.
No adverse reactions that could be related to the veterinary medicinal product were observed in dogs with otitis externa under field conditions when administered as indicated in section 4.9.
Kod pasa s vanjskim otitisom nisu bile uočene nuspojave u terenskim uvjetima, koje bi mogle biti povezane s veterinarsko-medicinskim proizvodom, kada se daje što je to naznačeno u odjeljku 4.9.
No adverse reactions that could be related to the veterinary medicinal product were observed in dogs with otitis externa under field conditions.
Kod pasa s vanjskim otitisom nisu bile uočene nuspojave u terenskim uvjetima, koje bi mogle biti povezane s veterinarsko-medicinskim proizvodom.
No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of solvent) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Poslije predoziranja (10 doza liofilizata + dvije doze otapala) veterinarsko-medicinskog proizvoda nisu primijećene druge nuspojave od onih već spomenutih u dijelu 4.6., osim lokalnih reakcija koje mogu trajati duže (najviše od 5-6 tjedana).
No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of solvent) of the veterinary medicinal product other than those mentioned in section 6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Nakon predoziranja (10 doza liofilizata + dvije doze otapala) veterinarsko-medicinskog proizvoda nisu primijećene druge nuspojave od onih već spomenutih u dijelu 6., osim lokalne reakcije koje mogu trajati duže (najviše od 5-6 tjedana).
No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Nakon predoziranja (dvije doze) veterinarsko-medicinskim proizvodom nisu opažene druge nuspojave do onih već spomenutih u dijelu 4.6, osim lokalnih reakcija koje mogu trajati duže (najviše 5-6 tjedana).
No adverse reactions were observed after the administration of an overdose (10x the dose).
Nisu zabilježene nuspojave nakon primjene uvećane doze (10 x veće doze).